Optimisation du bon usage et maîtrise des coûts des médicaments anticancéreux : expérience de l’Observatoire dédié au Cancer Bretagne – Pays-de-la-Loire

作者: Françoise Grudé , Réjane Bessard , Hugues Bourgeois , Jean-Yves Douillard , Erik Gamelin

DOI: 10.1684/BDC.2013.1715

关键词:

摘要: Optimizing the care management of patients is a major issue for our society. In Brittany-Pays-de-la-Loire (almost 10% French population), an observatory cancer has been created in 2003. Its main objective was follow-up expensive drugs. The knowledge use these drugs clinical practice led to development thesaurus good use. Thus, regular exchanges between clinicians have almost totally reduced not medically justified prescriptions by after and before administration patient. given away national guidelines from 2007. For example, two regions, optimization gemcitabine bevacizumab allowed save respectively 2.5 millions euros 2005 2008 3 2009 2010 (breast only). anticancer real health economy without any bad impact on patient management. Respecting medical ethics, remains optimize care. This highly participation currently allows reflect together relevance last chemotherapy.

参考文章(11)
I Debrix, M Sitbon, A Khalil, A Benomar, A Becker, T André, [Référentiel de bon usage and Thésaurus national de cancérologie digestive: analysis of non-conform prescriptions in Tenon hospital]. Bulletin Du Cancer. ,vol. 96, pp. 147- 155 ,(2009) , 10.1684/BDC.2008.0820
S. Van Hulst, E. Vuillemin, A.-C. Hardy-Bessard, M.-J. Goudier, H. Simon, B. Lucas, F. Priou, C. Riché, E. Gamelin, F. Grudé, M. Campone, A. Lortholary, R. Delva, P. Soulie, P. Kerbrat, G. Ganem, H. Bourgeois, Étude de phase IV de pharmacovigilance portant sur la toxicité cardiaque du trastuzumab en néoadjuvant et adjuvant dans le cancer du sein. Analyse conduite par l’Observatoire des Médicaments et des Innovations Thérapeutiques de Bretagne et des Pays de la Loire (OMIT B PL) Oncologie. ,vol. 12, pp. 362- 368 ,(2010) , 10.1007/S10269-010-1888-5
J. Metges, J. Raoul, N. Achour, O. Capitain, A. Gourlaouen, J. Ramée, J. Egreteau, J. Douillard, S. Traoré, F. Grudé, PANERB study: Panitumumab after cetuximab-based regimen failure. Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.E14000
T. Cloughesy, J. J. Vredenburgh, B. Day, A. Das, H. S. Friedman, , Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. Journal of Clinical Oncology. ,vol. 28, pp. 2008- 2008 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.2008
H. Bourgeois, F. Denis, P. Kerbrat, M. Combe, R. Lamy, J. Egreteau, V. Delecroix, P. Deguiral, S. Van Hulst, Y. Hadjarab, H. Simon, D. Berton-Rigault, F. Priou, A. Hardy-Bessard, M. Porneuf, Y. Raoul, H. Desclos, S. Abadie-Lacourtoisie, C. El Khouri, J. Metges, C. Riché, F. Grudé, Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: ALOPERS Observatory. Cancer Research. ,vol. 69, pp. 3174- 3174 ,(2009) , 10.1158/0008-5472.SABCS-09-3174
J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. M. Dowell, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, M. Wagner, D. D. Bigner, A. H. Friedman, H. S. Friedman, Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Clinical Cancer Research. ,vol. 13, pp. 1253- 1259 ,(2007) , 10.1158/1078-0432.CCR-06-2309
James J. Vredenburgh, Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John Sampson, Melissa Wagner, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman, Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme Journal of Clinical Oncology. ,vol. 25, pp. 4722- 4729 ,(2007) , 10.1200/JCO.2007.12.2440
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W.K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy, Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma Journal of Clinical Oncology. ,vol. 27, pp. 4733- 4740 ,(2009) , 10.1200/JCO.2008.19.8721
Teri N. Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Cheryl Royce, Irene Stroud, Nancy Garren, Megan Mackey, John A. Butman, Kevin Camphausen, John Park, Paul S. Albert, Howard A. Fine, Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma Journal of Clinical Oncology. ,vol. 27, pp. 740- 745 ,(2009) , 10.1200/JCO.2008.16.3055
Francoise Grude, Jean François Ramée, Laurent Guivarch, Jean-Yves Douillard, Sophie Rochard, Olivier Dupuis, Chrystelle Grollier, Veronique Guerin-Meyer, Pierre Leynia, Marc Porneuf, Elodie Peguet, Jean Luc Raoul, Claude Bertrand, Philippe Deguiral, Laurent Derenne, Nacredine Achour, Bernadette Person, Jean-Philippe Metges, Marie-Annick Lebot, Christian Riche, Efficacity and safety of panitumumab in mCRC patients: A post-AMM OMIT study. Journal of Clinical Oncology. ,vol. 30, pp. 608- 608 ,(2012) , 10.1200/JCO.2012.30.4_SUPPL.608